Dermal delivery
AssigneeAnterios, Inc.
InventorsJonathan Edelson, Timothy Kotyla, Boke Zhang
Life of this patent
Estimating the term…
Abstract
The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.
Claims171
A method comprising steps of:
- identifying a patient exhibiting at least one symptom of a disorder associated with the dermal level of the skin;
- and
- administering a nanoemulsion to the patient's skin so that at least one of the symptoms is reduced,
- wherein the nanoemulsion comprises a population of particles, wherein the majority of particles have diameters between approximately 10 and approximately 300 nanometers, wherein the nanoemulsion comprises:
- an aqueous dispersion medium;
- an oil;
- a surfactant
- at least one therapeutic agent
- wherein the oil and surfactant are present at a ratio ranging between 0.5 and 2.
A method comprising steps of:
- providing a patient exhibiting at least one symptom of acne;
- and
- administering a nanoemulsion to the patient's skin so that at least one of the symptoms is reduced,
- wherein the nanoemulsion comprises a population of particles, wherein the majority of particles have diameters between approximately 10 and approximately 300 nanometers, wherein the nanoemulsion comprises:
- an aqueous dispersion medium;
- an oil;
- a surfactant
- at least one therapeutic agent
- wherein the oil and surfactant are present at a ratio ranging between 0.5 and 2.
A method comprising steps of:
- identifying a patient exhibiting at least one symptom of hyperhidrosis;
- and
- administering a nanoemulsion to the patient's skin so that at least one of the symptoms is reduced,
- wherein the nanoemulsion comprises a population of particles, wherein the majority of particles have diameters between approximately 10 and approximately 300 nanometers, wherein the nanoemulsion comprises:
- an aqueous dispersion medium;
- an oil;
- a surfactant
- at least one therapeutic agent
- wherein the oil and surfactant are present at a ratio ranging between 0.5 and 2.
6-13. (canceled)
(canceled)
17-19. (canceled)
21-22. (canceled)
A method comprising steps of:
- providing a patient exhibiting at least one symptom of a condition or disorder selected from the group consisting of bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, dermal infection, actinic keratosis, eczematous dermatitis, excess sebum-producing disorder, Raynaud's phenomenon, lupus erthythematosus, hyperpigmentation disorder, hypopigmentation disorder, and skin cancer;
- and
- administering a nanoemulsion to the patient's skin so that at least one of the symptoms is reduced,
- wherein the nanoemulsion comprises a population of particles, wherein the majority of particles have diameters between approximately 10 and approximately 300 nanometers, wherein the nanoemulsion comprises:
- an aqueous dispersion medium;
- an oil;
- a surfactant
- at least one therapeutic agent
- wherein the oil and surfactant are present at a ratio ranging between 0.5 and 2.
25-38. (canceled)
(canceled)
(canceled)
(canceled)
59-64. (canceled)
72-73. (canceled)
(canceled)
78-80. (canceled)
(canceled)
86-87. (canceled)
89-90. (canceled)
(canceled)
(canceled)
96-97. (canceled)
102-103. (canceled)
(canceled)
110-111. (canceled)
113-114. (canceled)
120-121. (canceled)
131-133. (canceled)
(canceled)
(canceled)
144-146. (canceled)
(canceled)
168-172. (canceled)
179-180. (canceled)
184-186. (canceled)
(canceled)
190-191. (canceled)
201-223. (canceled)
231-234. (canceled)
(canceled)
Dependencies are inferred from the claim text.